$EVAX News

Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ...

Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?

Evaxion A/S 2026 Q2 - Results - Earnings Call Presentation

Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript

Evaxion announces business update and second quarter 2026 financial results

Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript

Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program

Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026

Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple Angles

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026

Evaxion receives Prix Galien UK Award for Best digital health solution

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion Says AI-Immunology-Developed EVX-04 Shows Immune Activation And Targeted Cell-Killing In Preclinical Acute Myeloid Leukemia Data

Evaxion A/S 2026 Q1 - Results - Earnings Call Presentation